Abstract

Purpose: To evaluate the 12-month efficacy and safety of intravitreal Dobesilate in dry age-related macular degeneration (ARMD). Patients and Methods: Thirty patients with visual impairment due to dry ARMD received a single intravitreal injection of Dobesilate in the study eye. Ophthalmic evaluation included fundoscopy, spectral-domain optical coherence tomography (SD-OCT) and best-corrected visual acuity (BCVA) prior to therapy and 1 week, 1 and 12-months after treatment. Main Outcome Measures: Mean change in BCVA. Retinal anatomy. Incidence of ocular and non-ocular adverse events. Results: There was a statistically significant increase in mean BCVA at 12 months compared with baseline (0.30±0.04 vs. 0.49±0.06 SEM) (p<0.001). BCVA increased in 26 of 30 eyes (86.7%) and only 4 eyes (13.3%) didn’t show any change. Intravitreal Dobesilate injection resulted in a significant improvement of outer retinal anatomy. Visual improvement was not correlated with age. No ocular or systemic events were reported during the follow-up period. Conclusions: This study confirms the safety of Dobesilate intravitreally injected, as well as the improvement in visual acuity and retinal anatomy at 12 months follow-up. Intravitreal Dobesilate may be a promising therapeutic strategy targeting the inflammatory component of dry ARMD.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.